Research and Markets has announced the addition of the "Fabry Disease - Pipeline Review, H2 2016" report to their offering.
Fabry Disease pipeline therapeutics constitutes close to 14 molecules. Out of which approximately 14 molecules are developed by Companies. Our latest report Fabry Disease - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Fabry Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
Fabry Disease Fabry disease is an inherited disorder. Fabry disease results from abnormal deposits of a particular fatty substance (called globotriaosylceramide) in blood vessel walls throughout the body. Symptoms include pain, diarrhea, nausea, kidney problems, tinnitus, irregular heartbeat, and leaky heart valves. Treatment includes enzyme replacement therapy (ERT). The molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 4, 2, 2 and 6 respectively.
Furthermore, this report also reviews of key players involved in therapeutic development for Fabry Disease and features dormant and discontinued projects.
Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/bhh4kd/fabry_disease
View source version on businesswire.com: http://www.businesswire.com/news/home/20160930005616/en/Business Wire
Last updated on: 30/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.